What does Evolutionary Genomics, Inc. do?

Evolutionary Genomics, Inc. (FNAM) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is FNAM's market cap?

Evolutionary Genomics, Inc. (FNAM) has a market capitalization of approximately $1,331, as of August 25, 2026, based on the most recent share price and shares outstanding.

Does FNAM pay a dividend?

No — Evolutionary Genomics, Inc. (FNAM) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Evolutionary Genomics, Inc. (FNAM) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

FNAM

Evolutionary Genomics, Inc.

OTC·Biotechnology · Healthcare

$0.00$0.00+0.00%

Market cap$1.33K·Market closed·Aug 25 8:00 PM UTC

Price Chart

$0.00+$0.00 (+0.00%)today

−99.98%CAGR −80.97%

Select date range

FromTo

May 15, 2012Aug 27, 2021 → Aug 27, 2026· 5.0 yrsAug 27, 2026

Key Metrics

FNAM does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateNov 29

Last Report DateMar 9

Reported vs Estimate−$0.04

Earnings Surprise—

FinancialsFinancials Tab

Revenue$0.00

Net Income−$1.86M

Net Margin—

Operating Cash Flow−$640.95K

Capital Expenditures$0.00

Free Cash Flow−$640.95K

Return on Equity—

Return on Invested Capital−18.9%

Net Debt$3.17M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for FNAM and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how FNAM's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for FNAM and 80,000+ other tickers.

About Evolutionary Genomics, Inc.

Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governmental organizations, non-profit foundations, and commercial entities. The company is based in Castle Rock, Colorado.

CEO: Steven Bryan Warnecke
Sector: Healthcare
Industry: Biotechnology
Exchange: OTC
Employees: 2
Website: www.evolgen.com

Peers

Viskase Companies, Inc.

Latest News

News Tab

No recent news available.

Frequently Asked Questions About FNAM

What does Evolutionary Genomics, Inc. do?: Evolutionary Genomics, Inc. (FNAM) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is FNAM's market cap?: Evolutionary Genomics, Inc. (FNAM) has a market capitalization of approximately $1,331, as of August 25, 2026, based on the most recent share price and shares outstanding.
Does FNAM pay a dividend?: No — Evolutionary Genomics, Inc. (FNAM) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is FNAM profitable?: Evolutionary Genomics, Inc. (FNAM) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.